GlassScriptPhysician profile
Joseph D Kassa
NPI 1548672397
$12,245.84
in general payments reported to CMS, 2019-2025
58 companies · $35.92 in 2025
The $35.92 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,478 · 2020: $1,432 · 2021: $1,817 · 2022: $3,100 · 2023: $1,940 · 2024: $1,443 · 2025: $35.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,397 · Education: $22.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,397.02 |
| Education | $22.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,395.49 | 2019-2024 | |
| Abbvie INC. | $1,235.57 | 2019-2024 | |
| Ucb, INC. | $1,134.40 | 2019-2024 | Briviact, Nayzilam, Fintepla |
| Biogen, INC. | $816.55 | 2019-2024 | Vumerity, Tysabri, Plegridy |
| Teva Pharmaceuticals USA, INC. | $693.66 | 2019-2024 | Ajovy, Austedo Xr, Austedo |
| Emd Serono, INC. | $574.48 | 2019-2023 | Mavenclad |
| Genzyme Corporation | $544.87 | 2019-2023 | |
| Amgen INC. | $439.53 | 2019-2024 | Uplizna, Aimovig |
| Lilly USA, LLC | $381.67 | 2019-2024 | Emgality, Amyvid, Reyvow |
| Celgene Corporation | $357.09 | 2021-2024 | Zeposia |
| Allergan, INC. | $284.57 | 2019-2022 | |
| Genentech USA, INC. | $254.75 | 2019-2025 | Enspryng, Ocrevus, Tnkase |
| Sunovion Pharmaceuticals INC. | $243.45 | 2019-2022 | |
| Eisai INC. | $227.89 | 2020-2024 | |
| Neurocrine Biosciences, INC. | $221.85 | 2019-2024 | Ingrezza, Ongentys |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Kassa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.